Patients with symptomatic nOH due to Parkinson disease , multiple system atrophy , pure autonomic failure , or nondiabetic autonomic neuropathy underwent open-label droxidopa dose optimization ( 100-600 mg 3 times daily ) , followed , in responders , by 7-day washout and then a 7-day double-blind trial of droxidopa vs placebo .